Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells

Environmental and Molecular Mutagenesis

Volumn 46, Issue 2, 2005, Pages 104-115

  Silva, Maria J ^a   Costa, Paula ^a   Dias, Anabela ^a   Valente, Marco ^a   Louro, Henriqueta ^a   Boavida, Maria G ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

Cisplatin; Hprt CHO; Mutant frequency; Mutation spectrum; Oxaliplatin

Indexed keywords

CISPLATIN; OXALIPLATIN;

ANIMAL CELL; ARTICLE; BASE PAIRING; CARCINOGENIC ACTIVITY; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DRUG ACTIVITY; DRUG STRUCTURE; GENE; GENE DELETION; GENE INSERTION; GENE SEQUENCE; HPRT GENE; MUTAGENIC ACTIVITY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CISPLATIN; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MUTAGENICITY TESTS; MUTAGENS; ORGANOPLATINUM COMPOUNDS;

EID: 24944546758     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.20138     Document Type: Article

References (59)

1. Adams WR, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391-396.
2. Bassett E, Vaisman A, Tropea KA, McCall CM, Masutani C, Hanaoka F, Chaney SG. 2002. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases β and η. DNA Repair 1:1003-1016.
3. Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M. 2004. The role of DNA polymerase η in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res 64:6469-6475.
4. Bleiberg H. 1998. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77 (Suppl. 4):1-3.
5. Bradley LJN, Yarema KJ, Lippard SJ, Essigmann JM. 1993. Mutagenicity and genotoxicity of the major DNA adduct of the antitumour drug cis- diamminedichloroplatinum(II). Biochemistry 32: 982-988.
6. Brower J, van de Putte P, Fichtinger-Schepman AMJ, Reedijk J. 1981. Base-pair substitution hotspots in GAG, GGG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). Proc Natl Acad Sci USA 78:7010-7014.
7. Burnouf D, Daune M, Fuchs RPP. 1987. Spectrum of cisplatin-induced mutations in Escherichia coli. Proc Natl Acad Sci USA 84:3758-3762.
8. Burnouf D, Gauthier C, Chottard JC, Fuchs RPP. 1990. Single d(ApG)/ cis-diamminedichloroplatinum (II) adduct-induced mutagenesis in Escherichia coli. Proc Natl Acad Sci USA 87:6087-6091.
9. Cariello NF, Swenberg JS, Skopek T. 1992. In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res 52:2866-2873.
10. Cariello NF, Piegorsch WW, Adams WT, Skopek TR. 1994. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 15:2281-2285.
11. Chaney SG. 1995. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Int J Oncol 6:1291-1305.
12. Cvitkovic E. 1998. Ongoing and unsaid of oxaliplatin: the hope. Br J Cancer 77:8-11.
13. de Boer JG, Glickman BW. 1989. Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene. Carcinogenesis 10:1363-1367.
14. Diwan BA, Anderson LM, Ward JM, Henneman JR, Rice JM. 1995. Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol Appl Pharmacol 132:115-121.
15. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM. 2003. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225-237.
16. Fichtinger-Schepman A, van der Veer JL, den Hartog J, Lohman P, Reedijk J. 1985. Adducts of the antitumour drug cis-diamminodichloroplatinum (II) with DNA: formation, identification and quantitation. Biochemistry 24:707-713.
17. Fink D, Zheng H, Nebel S. 1997. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57:1841-1845.
18. Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R. 1997. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14:185-193.
19. Harwood J, Meuth M. 1995. Deletion mapping of highly conserved transcribed sequence downstream from APRT locus. Somat Cell Mol Genet 21:151-160.
20. Hoffmann J-S, Pillaire M-J, Garcia-Estefania D, Lapalu S, Villani G. 1996. In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase β and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. J Biol Chem 271:15386-15392.
21. Hu T, Miller CM, Ridder GM, Aardema MJ. 1999. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutat Res 426: 51-62.
22. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A, Bohr VA. 1991. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266:7101-7107.
23. Jordan P, Carmo-Fonseca M. 2000. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235.
24. Kartalou M, Essigman JM. 2001. Mechanisms of resistance to cisplatin. Mutat Res 478:23-43.
25. Leopold WR, Barzinger RP, Miller EC, Miller JA, Earhardt RH. 1981. Mutagenicity, tumorigenicity and electrophilic reactivity of the stereoisomeric platinum (II) complexes of 1,2-diamminocyclohexane. Cancer Res 41:4368-4377.
26. Louro H, Silva MJ, Boavida MG. 2002. Mutagenic activity of cisplatin in the lacZ plasmid-based transgenic mouse model. Environ Mol Mutagen 40:283-291.
27. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P. 2003. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3:21-29.
28. Mis JRA, Kunz BA. 1990. Analysis of mutations induced in the SUP4-O gene of Saccharomyces cerevisiae by cis-diammine dichloroplatinum (II). Carcinogenesis 11:633-638.
29. Morris T, Thacker J. 1993. Formation of large deletions by illegitimate recombination in the hprt gene of primary human fibroblasts. Proc Natl Acad Sci USA 90:1392-1396.
30. Nehmé A, Rajasekaran B, Aebi S, Fink D, Nebel S, Cenni B, Wang JYJ, Howell SB, Christen RD. 1997. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 57:3253-3257.
31. Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JYJ, Christen RD. 1999. Induction of JNK, c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79:1104-1110.
32. Nelson SL, Jones IM, Fuscoe JC, Burkhart-Schultz K, Grosovsky AJ. 1995. Mapping the end points of large deletions affecting the hprt locus in human peripheral blood cells and cell lines. Radiat Res 141:2-10.
33. O'Dwyer PJ, Stevenson JP, Johnson SW. 1999. Clinical status of cisplatin, carboplatin and other platinum-based antitumour drugs. In: Lippert B, editor. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Zurich: VHCA. pp. 31-69.
34. Pillaire MJ, Margot A, Villani G, Sarasin A, Difais M, Gentil A. 1994. Mutagen in monkey cells of a vector containing a single d(GpG) cis-diamminedichloroplatinum (II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acids Res 22:2519-2524.
35. Piovesan B, Pennel N, Berinstein NL. 1998. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Oncogene 17:2339-2350.
36. Raymond E, Chaney SG, Taama A, Cvitkovic E. 1998a. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053-1071.
37. Raymond E, Faivre S, Woynarowski J, Chaney SG. 1998b. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25(Suppl. 5):4-12.
38. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. 1998c. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 4:1021-1029.
39. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. 1996. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52:1855-1865.
40. Rossiter BJF, Fuscoe JC, Muzni DM, Fox M, Caskey CT. 1991. The Chinese hamster HPRT gene: restriction map, sequence analysis, and multiplex PCR deletion screen. Genomics 9:247-256.
41. Sargent RG, Rolig RL, Kiburn AE, Adair GM, Wilson JH, Nairn RS. 1997. Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. Proc Natl Acad Sci USA 94:13, 122-13, 127.
42. Saris CP, Van de Vaart PJM, Rietbroek RC, Blommaert FA. 1996. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769.
43. Scheeff ED, Briggs JM, Howell SB. 1999. Molecular modelling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56:633-643.
44. Schwartz JL, Jordan R, Sun J, Ma H, Hsie AW. 2000. Dose-dependent changes in the spectrum of mutations induced by ionizing radiation. Radiat Res 153:312-317.
45. Seigneur M, Bidnenko SD, Erlich SD, Michel B. 1998. Ruv AB acts at arrested replication forks. Cell 95:419-430.
46. Travis LB, Andersson M, Gospodarowicz M, van Leewen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty EJ, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD, Stovall M, Gilbert E. 2000. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171.
47. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barret JC. 1998. The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585.
48. Vaisman A, Masutani C, Hanaoka F, Chaney SG. 2000. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase η. Biochemistry 39:4575-4580.
49. Valentine CR, Heflich RH. 1995. Genomic DNA sequencing of mRNA splicing mutants in the hprt gene of Chinese hamster ovary cells. Environ Mol Mutagen 25:85-96.
50. Vrieling H, Wijnhoven S, van Sloun P, Kool H, Giphart-Gassler M, van Zeeland A. 1999. Heterozygous Aprt mouse model: detection and study of a broad range of autosomal somatic mutations in vivo. Environ Mol Mutagen 34:84-89.
51. Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P. 1998. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777.
52. Woynarowski JM, Faivre S, Herzig MCS, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. 2000. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920-927.
53. Xu Z, Yu Y, Schwartz JL, Meltz ML, Hsie AW. 1995. Molecular nature of spontaneous mutations at the hypoxanthine-guanine phosphoribosyltransferase (hprt) locus in Chinese hamster ovary cells. Environ Mol Mutagen 26:127-138.
54. Yamada M, O'Regan E, Brown R, Karran P. 1997. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 25:491-495.
55. Yarema KJ, Lippard SJ, Essigman JM. 1995. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diammino dichloroplatinum (II). Nucleic Acids Res 23:4066-4076.
56. Zdraveski ZZ, Mello JA, Marinus MG, Essigman JM. 2000. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 7:39-50.
57. Zdraveski ZZ, Mello JA, Farinelli CK, Essigman JM, Marinus MG. 2002. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 277:1255-1260.
58. Zhang LH, Vrieling H, van Zeeland AA, Jensen D. 1992. Spectrum of spontaneously occurring mutations in the hprt gene of V79 Chinese hamster cells. J Mol Biol 223:627-635.
59. Zhen W, Link CJ, O'Connor PM. 1992. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12:3689-3698.